Aurinia Pharmaceuticals (NASDAQ:AUPH) Price Target Cut to $13.00

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) had its price target reduced by stock analysts at HC Wainwright from $15.00 to $13.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential […]

Related Keywords

United States ,Canada ,Blackrock ,Nova Scotia , ,Aurinia Pharmaceuticals Stock Performance ,Institutional Investors Weigh In On Aurinia Pharmaceuticals ,Blackrock Inc ,Aurinia Pharmaceuticals Inc ,Jefferies Financial Group ,Bellevue Group ,Armistice Capital ,Aurinia Pharmaceuticals ,News Ratings For Aurinia Pharmaceuticals Daily ,Royal Bank ,Otsuka Pharmaceutical Co Ltd ,Get Free Report ,Financial Group ,Street Corp ,Pharmaceuticals Inc ,Aurinia Pharmaceuticals Daily ,Nasdaq Auph ,Auph ,Medical ,Lower Price Target ,Hc Wainwright ,